BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 24262191)

  • 1. α-Synucleinopathy phenotypes.
    McCann H; Stevens CH; Cartwright H; Halliday GM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S62-7. PubMed ID: 24262191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropathology underlying clinical variability in patients with synucleinopathies.
    Halliday GM; Holton JL; Revesz T; Dickson DW
    Acta Neuropathol; 2011 Aug; 122(2):187-204. PubMed ID: 21720849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.
    Sasaki K; Doh-ura K; Wakisaka Y; Iwaki T
    Acta Neuropathol; 2002 Sep; 104(3):225-30. PubMed ID: 12172907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
    Peelaerts W; Bousset L; Baekelandt V; Melki R
    Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathological spectrum of synucleinopathies.
    Jellinger KA
    Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.
    Fernagut PO; Dehay B; Maillard A; Bezard E; Perez P; Pavy-Le Traon A; Rascol O; Foubert-Samier A; Tison F; Meissner WG
    Neurobiol Dis; 2014 Jul; 67():133-9. PubMed ID: 24727096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ɑ-Synuclein strains and the variable pathologies of synucleinopathies.
    Peelaerts W; Baekelandt V
    J Neurochem; 2016 Oct; 139 Suppl 1():256-274. PubMed ID: 26924014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
    Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
    Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated NUB1 distinguishes α-synuclein in Lewy bodies from that in glial cytoplasmic inclusions in multiple system atrophy.
    Tanji K; Miki Y; Mori F; Kon T; Kakita A; Takahashi H; Wakabayashi K
    Brain Pathol; 2019 Nov; 29(6):803-812. PubMed ID: 31006160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered α-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.
    Brudek T; Winge K; Rasmussen NB; Bahl JM; Tanassi J; Agander TK; Hyde TM; Pakkenberg B
    J Neurochem; 2016 Jan; 136(1):172-85. PubMed ID: 26465922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging synucleinopathies.
    Brooks DJ; Tambasco N
    Mov Disord; 2016 Jun; 31(6):814-29. PubMed ID: 26879635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
    Peelaerts W; Bousset L; Van der Perren A; Moskalyuk A; Pulizzi R; Giugliano M; Van den Haute C; Melki R; Baekelandt V
    Nature; 2015 Jun; 522(7556):340-4. PubMed ID: 26061766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
    Wales P; Pinho R; Lázaro DF; Outeiro TF
    J Parkinsons Dis; 2013; 3(4):415-59. PubMed ID: 24270242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy.
    Mori F; Piao YS; Hayashi S; Fujiwara H; Hasegawa M; Yoshimoto M; Iwatsubo T; Takahashi H; Wakabayashi K
    J Neuropathol Exp Neurol; 2003 Aug; 62(8):812-9. PubMed ID: 14503637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGAR inclusion pathology is specific for Lewy body diseases.
    López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
    Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synucleinopathy with features of both multiple system atrophy and dementia with Lewy bodies.
    Sikorska B; Papierz W; Preusser M; Liberski PP; Budka H
    Neuropathol Appl Neurobiol; 2007 Feb; 33(1):126-9. PubMed ID: 17239015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 47.